

## Expert Workshop: Expedited Drug Development for Promising Therapies

The Brookings Institution • Washington, DC December 15, 2011

## Agenda

- 8:00 a.m. Registration, Continental Breakfast
- 8:30 a.m. Welcome, Introduction, and Meeting Objectives Mark McClellan, Engelberg Center for Health Care Reform at Brookings
- 8:40 a.m. Panel 1: Existing Approaches for Expedited Market Access Gregory Daniel, Engelberg Center for Health Care Reform at Brookings – Moderator Rachel Sherman, U.S. Food and Drug Administration Margo Heath-Chiozzi, Bristol-Myers Squibb
- 9:30 a.m. Panel 2: Opportunities to Improve and Expand Existing Pathways Jeff Allen, Friends of Cancer Research – Moderator Janet Woodcock, U.S. Food and Drug Administration James C. Greenwood, Biotechnology Industry Organization Jonathan Leff, Warburg Pincus LLC Garry Neil, Johnson & Johnson
- 10:45 a.m. Break

10:55 a.m. Panel 3: Focus Areas for Expedited Drug Development Informed by Patient and Public Health Needs Gregory Daniel, Engelberg Center for Health Care Reform at Brookings – Moderator Daniel Perry, Alliance for Aging Research Peter Saltonstall, National Organization for Rare Disorders Naomi Aronson, Blue Cross and Blue Shield Association Technology Evaluation Center Russell Katz, U.S. Food and Drug Administration

- 12:00 p.m. Lunch
- 12:30 p.m. Panel 4: Innovative Methodologies for Expedited Evidence Development Mark McClellan – Moderator Robert Califf, Duke University Medical Center and Duke Translational Medicine Institute Donald Berry, University of Texas MD Anderson Cancer Center Jeffrey Murray, U.S. Food and Drug Administration
- 1:25 p.m. Panel 5: Post-Market Considerations to Ensure Safe Use and Continued Evidence Development Following Expedited Development and Approval Mark McClellan – Moderator Brian Solow, OptumRx Ellen Sigal, Friends of Cancer Research Richard Platt, Harvard Medical School and Harvard Pilgrim Health Care Institute Kathleen Hewitt, American College of Cardiology Louis Jacques, Centers for Medicare & Medicaid Services
- 2:20 p.m. Recap and Closing Remarks
  - Mark McClellan
- 2:30 p.m. Adjourn